|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.30 EUR | -3.26% |
|
+3.33% | +8.33% |
| Dec. 10 | Medincell Narrows Operating Loss in First Half |  |
| Dec. 10 | MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.08B | - | ||||
| 930B | |||||
| 527B | |||||
| 379B | |||||
| 371B | |||||
| 292B |
- Stock Market
- Equities
- MEDCL Stock
- Charts MedinCell S.A.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
